<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="polargo-rrdlbcl-matasar">
    <meta name="study:title" content="S101 - Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for R/R DLBCL: results from the Phase III POLARGO trial">
    <meta name="study:fileName" content="Abstracts/POLARGO-RRDLBCL-MATASAR-S101.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Chemotherapy,CIT,Pola-R-GemOx,R-GemOx">

    <title>S101: POLARGO Trial (Pola-R-GemOx in R/R DLBCL) (Matasar) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: S101 - The POLARGO Trial: Pola-R-GemOx in R/R DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=255 Randomized)</h4>
                    <p>R/R DLBCL pts (≥1 prior line), transplant-ineligible. Aim: Compare efficacy & safety of Pola-R-GemOx vs R-GemOx.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Phase III)</h4>
                    <p>Pola-R-GemOx (n=129) vs R-GemOx (n=126), Q3W up to 8 cycles. Primary endpoint: OS.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (mF/U: 24.6 mo)</h4>
                    <p>mOS: <span class="highlight-value">19.5 vs 12.5 mo</span> (HR 0.60, p=0.0017) <br>mPFS: 7.4 vs 2.7 mo (HR 0.37, p<0.0001) </p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Pola-R-GemOx significantly reduced risk of death by 40% vs R-GemOx, with manageable safety. Reinforces benefit of Pola + chemo in DLBCL.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">S101 - Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from the randomized Phase III POLARGO trial</h1>
            <p class="abstract-sub-header">Matthew Matasar, Zhiming Li, Theodoros P. Vassilakopoulos, et al. </p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #S101 | Oral Presentation </p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Polatuzumab vedotin (Pola) is a CD79b-directed antibody-drug conjugate (ADC) that targets and kills B-cells.</li>
                        <li>Pola is approved for use in both first-line (Pola-R-CHP) and relapsed/refractory (R/R) DLBCL (Pola-BR).</li>
                        <li>The POLARGO trial (NCT04182204) was designed to evaluate the benefit of Pola-R-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL patients.</li>
                    </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Phase III, randomized, open-label trial in patients with transplant-ineligible R/R DLBCL after at least one prior line of therapy.</li>
                        <li>The study included an initial safety run-in cohort (n=15) treated with Pola-R-GemOx.</li>
                        <li>In the randomized phase, patients were assigned 1:1 to receive either Pola-R-GemOx or R-GemOx every 3 weeks for up to 8 cycles.</li>
                        <li>Pola dose was 1.8 mg/kg.</li>
                        <li>Stratification factors included age, number of prior therapies, and relapsed vs refractory status.</li>
                        <li>Primary endpoint: Overall Survival (OS). Key secondary endpoints: Progression-Free Survival (PFS, by investigator), Complete Response (CR, by IRC), and Overall Response Rate (ORR, by IRC).</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">POLARGO Trial Design</h3>
                        <div class="schema-enrollment">
                            <strong>R/R DLBCL, Transplant-ineligible, ≥1 prior LOT</strong>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-center mb-2">
                             <div class="schema-phase cohort-a" style="flex-basis: 60%;">
                                <strong>Safety Run-in (n=15)</strong>
                                <span>Pola-R-GemOx Q3W</span>
                                <span class="text-xs">(EP: Safety & Tolerability)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-enrollment">
                            <strong>Randomized Phase (N=255)</strong>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase cohort-a" style="flex-basis: 48%;">
                                <strong>Pola-R-GemOx Arm (n=129)</strong>
                                <span>Pola (1.8mg/kg) + R-GemOx</span>
                                <span>Q3W, up to 8 cycles</span>
                            </div>
                             <div class="schema-phase cohort-b" style="flex-basis: 48%;">
                                <strong>R-GemOx Arm (n=126)</strong>
                                <span>Rituximab + Gemcitabine + Oxaliplatin</span>
                                <span>Q3W, up to 8 cycles</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Primary EP: OS</span>
                           <span>Secondary EPs: PFS (INV), CRR, ORR (IRC)</span>
                           <span>Safety & Tolerability</span>
                        </div>
                    </div>
                </div>

                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics</h2>
                    <p class="text-sm mb-2">Baseline characteristics were well-balanced between the Pola-R-GemOx (n=129) and R-GemOx (n=126) arms.</p>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Pola-R-GemOx (n=129)</th><th>R-GemOx (n=126)</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>67 (20-85)</td><td>64 (24-89)</td></tr>
                                <tr><td>Age >70 years, %</td><td>34.9%</td><td>34.9%</td></tr>
                                <tr><td>ECOG PS 0-1, %</td><td>89.1%</td><td>87.3%</td></tr>
                                <tr><td>Stage III-IV, %</td><td>75.2%</td><td>77.8%</td></tr>
                                <tr><td>IPI Score 3-5, %</td><td>48.8%</td><td>50.0%</td></tr>
                                <tr><td>Refractory to Last Tx, %</td><td>65.9%</td><td>65.9%</td></tr>
                                <tr><td>Cell of Origin (ABC/GCB), %</td><td>31.8 / 37.2</td><td>35.7 / 39.7</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary</h2>
                    <div class="table-container">
                        <table class="safety-table">
                             <thead>
                                <tr><th>Adverse Event</th><th>Pola-R-GemOx (n=128)</th><th>R-GemOx (n=125)</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Any AE (Grade ≥3)</td><td>73 (57.0%)</td><td>73 (58.4%)</td></tr>
                                <tr><td>Serious AEs</td><td>49 (38.3%)</td><td>39 (31.2%)</td></tr>
                                <tr><td>Grade 5 AEs</td><td>15 (11.7%)</td><td>5 (4.0%)</td></tr>
                                <tr><td>Deaths due to PD</td><td>38 (29.7%)</td><td>70 (56.0%)</td></tr>
                                <tr><td>Thrombocytopenia (Grade ≥3)</td><td>44 (34.4%)</td><td>33 (26.4%)</td></tr>
                                <tr><td>Neutropenia (Grade ≥3)</td><td>43 (33.6%)</td><td>38 (30.4%)</td></tr>
                                <tr><td>Infections (Grade ≥3)</td><td>28 (21.9%)</td><td>12 (9.6%)</td></tr>
                                <tr><td>Peripheral Neuropathy (Any Grade)</td><td>73 (57.0%)</td><td>36 (28.8%)</td></tr>
                                <tr><td>Peripheral Neuropathy (Grade ≥3)</td><td>5 (3.9%)</td><td>0 (0%)</td></tr>
                            </tbody>
                        </table>
                         <p class="text-xs mt-2">Source:. Safety population n=128 for Pola-R-GemOx and n=125 for R-GemOx.</p>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 24.6 months )</h2>
                    <p class="text-sm font-semibold">Response Rates by PET-CT at EOT (IRC-assessed) </p>
                     <div class="chart-container mb-6">
                        <svg id="polargoResponseChart" width="400" height="300"></svg>
                        <div id="polargoResponseLegend" class="legend"></div>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-4">
                        <li><strong>Overall Survival (OS):</strong> Pola-R-GemOx significantly improved OS, with a median OS of 19.5 months vs 12.5 months for R-GemOx. The stratified HR was 0.60 (p=0.0017). Unstratified analysis showed an HR of 0.64 (95% CI: 0.47-0.89).</li>
                        <li><strong>Progression-Free Survival (PFS):</strong> PFS was also significantly improved, with a median PFS of 7.4 months for Pola-R-GemOx vs 2.7 months for R-GemOx. The stratified HR was 0.37 (p<0.0001). Unstratified analysis showed an HR of 0.46 (95% CI: 0.34-0.62).</li>
                        <li>The survival benefit of Pola-R-GemOx was consistent across most subgroups, including both ABC and GCB cell-of-origin types.</li>
                    </ul>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-4 mt-4">
                        <div class="km-plot-container zoomable-image-container">
                            <img src="https://www.onclive.com/view/pola-r-gemox-elicits-os-benefit-vs-r-gemox-in-transplant-ineligible-r-r-dlbcl" alt="Overall Survival Kaplan-Meier Curve - Placeholder" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/600x400/E0F2F7/0A2F5C?text=OS+Curve+(from+Source)';">
                            <p class="text-xs text-center mt-1">Overall Survival (Illustrative) </p>
                        </div>
                        <div class="km-plot-container zoomable-image-container">
                             <img src="https://www.onclive.com/view/pola-r-gemox-elicits-os-benefit-vs-r-gemox-in-transplant-ineligible-r-r-dlbcl" alt="Progression-Free Survival Kaplan-Meier Curve - Placeholder" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/FFF0E5/0A2F5C?text=PFS+Curve+(from+Source)';">
                            <p class="text-xs text-center mt-1">Progression-Free Survival (Illustrative) </p>
                        </div>
                    </div>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Subsequent Therapies</h2>
                    <p class="text-sm mb-2">Fewer patients in the Pola-R-GemOx arm required subsequent anticancer therapy compared to the R-GemOx arm.</p>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Subsequent Therapy</th><th>Pola-R-GemOx (n=129)</th><th>R-GemOx (n=126)</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Patients with ≥1 subsequent therapy</td><td>59 (45.7%)</td><td>82 (65.1%)</td></tr>
                                <tr><td>CAR T-cell therapy</td><td>12 (9.3%)</td><td>15 (11.9%)</td></tr>
                                <tr><td>Bispecific regimen</td><td>9 (7.0%)</td><td>8 (6.3%)</td></tr>
                                <tr><td>Pola-containing regimen</td><td>1 (0.8%)</td><td>14 (11.1%)</td></tr>
                            </tbody>
                        </table>
                        <p class="text-xs mt-2">Source:.</p>
                    </div>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Conclusion</h2>
            <p class="text-sm">In the Phase III POLARGO trial, Polatuzumab vedotin combined with R-GemOx significantly improved overall survival and progression-free survival compared with R-GemOx alone in transplant-ineligible patients with relapsed/refractory DLBCL. The safety profile was manageable and consistent with the known risks of the individual agents.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">Reference</h2>
            <p id="referenceSectionContent">Matasar M, Li Z, Vassilakopoulos TP, et al. Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from the randomized phase III POLARGO trial. Abstract #S101 presented at the European Hematology Association (EHA) Congress. 12-15 June 2025, Milan, Italy. </p>
        </div>
        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #S101 | Presentation: 06/14/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script>
     <script>
    function drawPolargoResponseChart(containerId, legendContainerId) {
        const chartTitle = "Response Rates by PET-CT at EOT (IRC-assessed)";
        const chartData = [
            { group: "Pola-R-GemOx (n=129)", CR: 40.3, PR: 12.4, Other: 47.3 }, // ORR 52.7%
            { group: "R-GemOx (n=126)", CR: 19.0, PR: 5.6, Other: 75.4 }    // ORR 24.6%
        ];
        const subgroups = ["CR", "PR", "Other"];
        const subgroupsDisplay = { "CR": "Complete Response", "PR": "Partial Response", "Other": "No Response / PD / SD" };

        const svg = d3.select(containerId);
        const legendContainer = d3.select(legendContainerId);
        svg.selectAll("*").remove();
        legendContainer.selectAll("*").remove();

        let containerWidth = 400;
        const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
        if (chartWrapper) {
            containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.95, 300);
        }
        
        const svgWidth = containerWidth;
        const svgHeight = +svg.attr("height");
        const margin = { top: 60, right: 20, bottom: 70, left: 60 };
        const chartWidth = svgWidth - margin.left - margin.right;
        const chartHeight = svgHeight - margin.top - margin.bottom;

        if (chartWidth <= 0 || chartHeight <=0) return;

        const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);
        const groups = chartData.map(d => d.group);
        
        const xScale = d3.scaleBand().domain(groups).range([0, chartWidth]).padding(0.4);
        const yScale = d3.scaleLinear().domain([0, 100]).range([chartHeight, 0]);
        const color = d3.scaleOrdinal().domain(subgroups).range(["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-medium-gray-text)"]);

        const stack = d3.stack().keys(subgroups);
        const stackedData = stack(chartData);

        g.append("g").attr("transform", `translate(0,${chartHeight})`).call(d3.axisBottom(xScale))
            .selectAll("text").attr("class", "axis-text").style("font-size", "9px").attr("transform", "rotate(-10) translate(-5,0)").style("text-anchor", "end");
        g.append("g").call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
            .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
        g.append("g").attr("class", "grid").call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat("")).selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

        const series = g.selectAll(".serie").data(stackedData).enter().append("g").attr("fill", d => color(d.key));
        
        series.selectAll("rect")
            .data(d => d)
            .enter().append("rect")
              .attr("x", d => xScale(d.data.group))
              .attr("y", d => yScale(d[1]))
              .attr("height", d => yScale(d[0]) - yScale(d[1]))
              .attr("width", xScale.bandwidth())
              .attr("rx", 2).attr("ry", 2);

        series.selectAll("text")
            .data(d => d)
            .enter().append("text")
            .filter(d => (d[1] - d[0]) > 5)
            .attr("class", "chart-label")
            .attr("x", d => xScale(d.data.group) + xScale.bandwidth() / 2)
            .attr("y", d => yScale(d[1]) + (yScale(d[0]) - yScale(d[1])) / 2 + 4)
            .attr("text-anchor", "middle")
            .style("font-size", "9px")
            .style("fill", d => ((d[1]-d[0]) > 15 || d.key === 'Other') ? "white" : "var(--sobi-dark-text)")
            .text(d => `${(d[1] - d[0]).toFixed(1)}%`);
            
        chartData.forEach(d => {
            const orr = d.CR + d.PR;
            g.append("text")
             .attr("class", "chart-label orr-label")
             .attr("x", xScale(d.group) + xScale.bandwidth() / 2)
             .attr("y", yScale(orr) - 8)
             .attr("text-anchor", "middle")
             .style("font-weight", "600").style("font-size", "10px").style("fill", "var(--sobi-dark-blue)")
             .text(`ORR: ${orr.toFixed(1)}%`);
        });

        svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2).attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600").style("fill", "var(--sobi-dark-blue)").text(chartTitle);

        const legendData = subgroups.map(key => ({ label: `${subgroupsDisplay[key]}`, color: color(key) }));
        const legendItems = legendContainer.selectAll(".legend-item").data(legendData).enter().append("div").attr("class", "legend-item");
        legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
        legendItems.append("span").text(d => d.label);
    }
    
    function debounce(func, wait) { let timeout; return function executedFunction(...args) { const later = () => { clearTimeout(timeout); func(...args); }; clearTimeout(timeout); timeout = setTimeout(later, wait); }; };
    const debouncedDrawChart = debounce(() => drawPolargoResponseChart("#polargoResponseChart", "#polargoResponseLegend"), 250);
    window.addEventListener('resize', debouncedDrawChart);
    document.addEventListener('DOMContentLoaded', debouncedDrawChart);
    if (document.readyState === "complete" || document.readyState === "interactive") { setTimeout(debouncedDrawChart, 0); }
    </script>
</body>
</html>